COMPASS study (COMPASS study)

Active, not recruiting

• Conditions: Eosinophilic Chronic Rhinosinusitis

• Registration Number: jRCT1050240216
• Lead Sponsor: AstraZeneca K.K.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-12-17
• Study Start: 2024-12-26
• Last Update Posted: 2025-01-28

Recruitment & Eligibility

• Status: Not Recruiting
• Sex: Not specified
• Target Recruitment: 200

Inclusion Criteria

1. Provision of signed informed consent on the website
2. Aged >=18 years at the time of answering the web survey
3. History of ECRS diagnosis more than 3 months prior to the time of answering the web survey
4. The patients who have been receiving CRS related treatment
5. The patients who have been issued a beneficiary certificate for intractable ECRS

Exclusion Criteria

None.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
-		Proportion of patient who are satisfied with current ECRS treatment

Secondary Outcome Measures

Name	Time	Method
Mean SNOT-22 score (total and each subdomain score)		-Proportion of patients with each category of SNOT-22 total score; -Proportion of patients with each category of SNOT-22 subdomain score; -Proportion of patients with each SNOT-22 cough score
Proportion of patient who are satisfied with current ECRS treatment by biologics use/non biologics use		-Mean SNOT-22 score (total and each subdomain score) by biologics use/non-biologics; -Proportion of patients with each category of SNOT-22 total score by biologics use/non-biologics; -Proportion of patients with each category of SNOT-22 subdomain score by biologics use/non-biologics; -Proportion of patients with each SNOT-22 cough score by biologics use/non-biologics; -Proportion of patients with not well-controlled asthma (ACT <20) by biologics use/non-biologics